Xpovio’s Solid Tumor Debut Faces Likely Three-Year Delay

 
• By Alaric DeArment

Karyopharm will conduct another trial of the drug in p53 wild-type endometrial cancer after the FDA said SIENDO data were insufficient for approval.

Cancer
Karyopharm said the FDA told it during a meeting that topline trial results would not likely be sufficient for Xpovio's approval in endometrial cancer • Source: Shutterstock

More from Anticancer

More from Therapy Areas